• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The novel compositions containing conjugated linoleic acid are useful as animal feed and human dietary supplements. The composition obtained by converting linoleic acid to its conjugated form contains less of some abnormal isomers as compared to conventional conjugated linoleic acid products.
    公开号:KR20010074447A
    申请号:KR1020007010266
    申请日:1999-03-17
    公开日:2001-08-04
    发明作者:아스게이르 사에보；칼 스카리에；다리아 제롬；구드문더 하랄드슨
    申请人:추후제출；콘린코 인크.；
    IPC主号:
    专利说明:

    Conjugated Linoleic Acid Compositions
    [2] In 1978, researchers at the University of Wisconsin discovered what was contained in cooked beef that exhibited mutation inhibition. This material was found to be a mixture of positional isomers of linoleic acid with conjugated double bonds (C18: 2). Although the c9, t11 and t10, c12 isomers are most present, it is not clear which isomers exhibit biological activity. From the labeled uptake studies, 9,11 isomers have been found to be somewhat preferred and included in the phospholipid fraction of animal tissue, with 10,12 isomers showing small amounts [Ha, et al., Cancer Res., 50: 1097 (1991).
    [3] The biological activity associated with conjugated linoleic acid (term CLA) is diverse and complex. Several preclinical and clinical studies are underway to reveal new methods of physiological and biochemical action, but little is known about the mechanism of action. The anticancer properties of CLA are well known. Administration of CLA inhibits tumor development of the breast of rats as described in HA, et al., Cancer Res., 52: 2035s (1992). Ha, et al., Cancer Res., 50 : 1097 (1990), reported similar results in a rat metastasis tumor model. CLA has also been found to be a strong cytotoxic agent against melanoma, colorectal and breast cancer cells of humans targeted in vivo. A recent major introduction has established conclusions drawn from individual studies [Ip, Am. J. Clin. Nutr., 66 (6 Supp): 1523 s (1997).
    [4] Although the mechanism of CLA action is still uncertain, there is evidence that at least some components of the immune system may be involved in vivo. US Pat. No. 5,585,400 to Cook et al., Incorporated herein by reference only, describes a method of reducing allergic or TgE hypersensitivity reactions in animals mediated by Type I by administering food containing CLA. CLA at a concentration of about 0.1-1.0% has also been found to be an effective adjuvant for the preservation of white blood cells. Cook et al., US Pat. No. 5,674,901, which is incorporated herein by reference only, discloses that the oral or parenteral administration of CLA in the form of free acid or salt increases the CD-4 and CD-8 lymphocyte subgroups involved in cell mediated immunity. It is stated to bring. In animals administered CLA, the deleterious effects of pretreatment with exogenous tumor necrosis factor can be alleviated by raising or maintaining CD-4 and CD-8 cell levels. Finally, US Pat. No. 5,430,066, incorporated herein by reference only, describes the effect of CLA in preventing weight loss and loss of appetite by immune stimulation.
    [5] Apart from the potential for therapeutic and pharmaceutical use of CLA as described above, there have been several attempts to consider nutritionally using CLA as a dietary supplement. CLA has been found to redistribute significant overall effects on body composition, particularly obesity and deficient tissue. US Pat. No. 5,554,646 (Cook, et al.), Incorporated herein by reference only, describes a method of using CLA as a dietary supplement to allow pigs, rats, and humans to eat food containing 0.5% CLA. have. For each species, a significant decrease in fat content was observed, accompanied by an increase in protein. Interestingly, in these animals, the increase in dietary fatty acid content due to the addition of CLA did not result in an increase in body weight, but was associated with the redistribution of obesity and deficiency in the body. Another interesting dietary phenomenon is that CLA supplementation affects feed conversion. US Pat. No. 5,428,072 (Cook, et al.), Incorporated herein by reference only, incorporated CLA into animal feed (birds and mammals), resulting in increased feed conversion efficiency resulting in more weight gain in animals supplemented with CLA. Provide data indicating the presence of a. It is clear that the supplementation of CLA has a beneficial effect on food animal breeders.
    [6] Another interesting source of interest for CLA whose initial commercial potential is foreseen is that it is naturally produced in food and feed consumed by humans, animals and the like. In particular, CLA is abundant in products obtained from ruminants. For example, some studies have been conducted by examining CLA in various dairy products. In Aneja, et al., J. Dairy Sci., 43: 231 (1990), the concentration of CLA was observed as a result of processing milk with yogurt. Shanta, et al., Food Chem., 47: 257 (1993) found that increasing the processing temperature and the addition of whey resulted in an increase in the concentration of CLA during the manufacture of processed cheese. In a separate study, Shanta, et al., J. Food Sci., 60: 695 (1995) did not reduce the concentration of CLA to the extent that processing and storage conditions were detectable, but no increase was observed. It is reported. In fact, some studies suggest that seasonal or animal changes may make up to three times the difference in milk CLA content [Parodi, et al., J. Dairy Sci., 60: 1550 (1977). )]. See also Chin, et al., J. Food Camp. Anal., 5: 185 (1992), the food factor was also associated with the change in CLA content. Changes in CLA content in these natural sources do not guarantee that ingestion of a specified amount of various foods is the optimal dosage needed by an individual or animal to achieve the desired nutritional effect.
    [7] Linoleic acid is an important component of biolipids and contains significant amounts of triglycerides and phospholipids. Linoleic acid is known as an "essential" fatty acid, meaning that the animal must obtain it from an external food source because it is not self-synthesizing. When linoleic acid is incorporated in the form of CLA, CLA can be directly substituted with the lipid position to which nonconjugated linoleic acid will move. However, this is not proven, and some of the observed effects that are very beneficial but not explained may be due to the relocation of CLA in the lipid structure at the site where nonconjugated linoleic acid would not have migrated if the CLA had not been rearranged. It is evident that one source of animal CLA, particularly in dairy products, stems from the biochemical action of some ruminant bacteria on natural linoleic acid, which first isomerizes linoleic acid to CLA and then secretes it into the ruminant cavity. Kepler et al. Isolated Butyrivibrio fibrisolvens , a ruminant bacterium that catalyzes the formation of 9,11-CLA as an intermediate in the biohydrogenation of linoleic acid (Kepler, et al., J. Nutrition, 56: 1191 (1966)). Chin et al. Further found that CLAs found in rodent tissue are related to bacteria because corresponding mice without bacteria do not produce CLA.
    [8] The development of determined commercial sources of CLA for therapeutic and nutritional use requires a method for generating large quantities of determined material. The problem associated with most CLA products produced by conventional approaches is the significant variation of the isomorphic form due to its heterogeneity and placement. Significant attention has been drawn to the fact that large intakes of hydrogenated oils and shortenings instead of animal oils have a high dietary effect on trans-fatty acid content. For example, Holman, et al., PNAS, 88: 4830 (1991) reported that feeding mice hydrogenated oils is an abnormal polyunsaturated fatty acid isomer that appears to interfere with normal metabolism of naturally occurring polyunsaturated fatty acids. Rats have been shown to increase intrahepatic accumulation. This relationship is described in Am. J. Public Health, 84: 722 (1974). There is therefore a strong need for CLA products of determined composition that are biologically active.
    [9] Summary of the Invention
    [10] The present invention provides novel compositions of isomerized fatty acids derived from purified food grade seed oils. In practical terms, the linoleic acid contained in the seed oil selected to contain at least 50% linoleic acid is usually present in excess of 90% of the 9,12-octadecadienoic acid isomer. During isomerization, 9,12-octadecadienoic acid is converted to a mixture of other isomers to form a composition containing at least 50% CLA.
    [11] Compositions containing conjugated linoleic acid are intended to be consumed by humans and animals, including edible animals such as cattle, pigs, sheep and birds as human medicines and nutritional supplements. It is an important object of the present invention to provide a safe and determined product for this purpose. Conventional products also contain significant amounts of unknown fatty acid species and abnormal isomers resulting from processing. Among the abnormal CLA isomers are the 11,13-octadecadienoic acid and the 8,10-octadecadienoic acid isomer.
    [12] In the compositions of the present invention, a carefully controlled reaction converts a high proportion of linoleic acid in the yield of at least 90% of these isomers to the conjugated c9, t11 and t10, c12 isomers, thus unlike 11,13 There are less than 1% mixed components of the isomers, less than 1% of the 8,10 isomers, less than 1% of the dual trans species (t9, t11 and t10, t12 isomers), and less than 1% of unidentified linoleic acid species in total. In many individual production runs, the final composition is contained at levels that are virtually undetectable by this species GC analysis. The 1% limit in concentrations of 11,13, 8,10 and trans-trans isomers serves as a convenient and practical quality assurance standard for purity for food grade products manufactured on a commercial scale.
    [13] The present invention also provides a novel process for preparing a composition containing the novel conjugated linoleic acid of the required purity and determined composition. In the absence of a metal-based isomerization catalyst system, the organic solvents such as alkali, or tetraethyl ammonium hydroxide, are compatible with a specific non-aqueous solvent, propylene glycol, with a non-aqueous medium such as potassium hydroxide, cesium hydroxide, cesium carbonate. Dissolving the alkali, blending the seed oil with alkaline propylene glycol, heating under non-reflux conditions to a temperature in the range of 130 to 165 ° C., preferably to about 150 ° C., under an inert gas atmosphere at ambient pressure, Separating the fatty acid fraction by acidification and optionally purifying and dehydrating by vacuum molecular distillation and / or centrifugation. In some cases such a process stream may comprise a step in which the reaction mixture is prepared before or after the heating step. This mixture can then be stored for further processing in subsequent acidification and distillation steps and / or further processed at another location. After heating to effectively isomerize, the isomerized blended reaction mixture contains 30 to 60% of the processed seed oil, 10 to 40% of the alkali, and 30 to 60% of propylene glycol. In this method it is important to use propylene glycol because of the heating properties and the pattern of isomerization obtained. The components of the dissolved fatty acid reaction mixture are present as follows.
    [14] Seed oil 30 to 60%
    [15] 10-40% alkali
    [16] Propylene Glycol 30-60%
    [17] Thus, in some embodiments, the method comprises forming a blended reaction mixture containing linoleic acid containing seed oil, propylene glycol, and an alkali compatible with a non-aqueous medium, wherein the seed oil is contained in the seed oil by heating. Isomerizing the linoleic acid to form conjugated linoleic acid, and aqueous to release the glycerol. Toxicities that can arise when other unwanted solvents such as ethylene glycol are used are avoided. It is also possible to use oils of various fatty acid compositions under non-refluxing conditions to change the processing temperature beyond the range to achieve the desired result. As in the percentage of trans, trans species, temperature is critical, and likewise other unidentified species also increase with increasing temperature. Processing times require about 2 to 6.5 hours, yielding isomerized yields of at least 90%, often at least 99.5%. In some embodiments the seed oil containing linoleic acid may first be treated to produce alkylesters of linoleic acid (eg, methyl esters or ethyl esters). In another embodiment the conjugated linoleic acid produced may be incorporated into triglycerides by treatment with lipolytic enzymes in the presence of glycerol. In another embodiment, the present invention provides a method for producing CLA having low impurities by the above method.
    [18] In the process of the present invention sunflower and safflower oils are used because of the high natural content of 9,12 linoleic acid as well as low levels of sterols, contaminating phospholipids, and other residues that contaminate processing equipment and result in less pure final products. It is desirable to. Other seed oils, such as corn, soybean and rinse oil, may also be used, but the final product may be less compositionally defined, and the level of impurities may be closer to the threshold of qualitative control considered above, and the isomerization process It can't predict itself. Although seed oils containing at least 50% linoleic acid are practically desirable for isomerization in the plant to obtain the best yield at each process step, the process of starting with materials containing linoleic acid, whether low or high in linoleic acid, is preferred. There is no limit. Low linoleic acid content can result in low linoleic acid content, such as when oil is mixed with non-oil components prior to blending or isomerizing oils from other sources. Similarly, the linoleic acid content of the isomerized fluid can be much higher than the values present in the seed oil, such as when isomerized with purified or synthesized linoleic acid.
    [19] In some embodiments, CLA with less impurities described above may be provided as acylglycerol or alkylesters. Thus, in some embodiments, the acylglycerol composition comprises a plurality of acylglycerol molecules of the formula: at least about 30% t10, c12 octadecadienoic acid, c9, t11 octadecadienoic acid, in the R 1 , R 2, and R 3 positions At least about 30%, and less than about 1% total 8,10 octadecadienoic acid, 11,13 octadecadienoic acid and trans-trans octadecadienoic acid.
    [20]
    [21] In which R isOne, R2And R3Is selected from the group consisting of hydroxyl groups and octadecadiic acid.
    [22] Likewise, in another embodiment there is provided a conjugated linoleic acid composition comprising a mixture of isomers of conjugated linoleic acid esters, the mixture comprising at least about 30% t10, c12 octadecadienoic acid and at least about 30% c9, t11 octadecadienoic acid And 8,10 octadecadienoic acid, 11,13 octadecadienoic acid and trans-trans octadecadiic acid in less than 1% total.
    [23] In another embodiment, the CLA free fatty acids, acylglycerols and alkylesters of the present invention can be made into food including animal feed and food for human consumption. In another embodiment, the CLA compositions of the present invention may be formulated with a physiologically acceptable carrier or oral delivery vehicle. In another embodiment, the biological effects of low impurity CLA can be exploited.
    [24] In the present invention, feed or food-safe conjugated linoleic acid alkyl esters isomerized to the desired 10,12 and 9,11 isomers, but 8,10; 11,13; And the formation of trans, trans species is prepared under conditions that are preferably controlled to limit. This condition is met by using an alkali alcoholate catalyzed reaction in which the seed oil separates to release free fatty acids in the glycerol backbone, esterify and then isomerize. An important point in applying this method to commercially viable production is the reduction of costly process steps. Usually residues derived from non-oil components of seed oils such as sterols and phospholipids contaminate the device and make it unsuitable for feed or food use. In the case of typical seed oils such as soy or corn, a significant amount of these residues is present and therefore the CLA-ester product cannot be used as a consuming product.
    [25] In the compositions of the present invention, rather than purifying non-oil residues from the oil component, the source of oil is selected to include such residues at acceptable levels. By selecting safflower or sunflower oil as the oil source, the critical value of the residues is 0.1 to 0.5% of phospholipids and non-saponifiable sterol fractions without camphorsterol and stigmasterol, respectively, without further degumming and distillation process steps. To be less than 20%. The linoleic acid alkyl esters obtained comprise octadecanoic acid esters representing a combination of various possible individual percentages of c9, t11-octadecanoic acid alkyl esters and t10, c12-octadecanoic acid alkyl esters from at least 50% by weight up to about 99% by weight. do. Each of these ester isomers is produced in approximately equal amounts in the alkali alcoholate catalyzed process, but the relative percentages can be varied by the addition of one composition rich in one isomer. The CLA ester is then blended from the conventional ingredients of a typical daily feed of the animal according to species and age, with the conjugated linoleic acid alkyl ester at a biologically active concentration, usually about 0.05 to 3.5% by weight. Blended and incorporated into animal feed.
    [26] The CLA-ester product of the present invention is obtained by direct isomerization of the unrefined linoleic acid, ie, the linoleic acid from which the linoleic acid source has not been subjected to the purification step. The first portion of the CLA-ester composition comprises at least 50 wt% (up to almost 100%) ester isomers of a mixture of c9, t11-octadecanoic acid esters and ester isomers of t10, c12-octadecanoic acid esters The portion comprises less than about 10% of the total weight of the ester isomers of 8,10-octadecanoic acid ester, 11,13-octadecanoic acid ester, and trans-trans octadecanoic acid ester, and the third portion comprises the total weight of the composition Phospholipid residue of 0.1 to 0.5%. The alkyl group can be methyl, ethyl, propyl, isopropyl, butyl, isobutyl and the like. The concentration of the c9, t11 and t10, c12 isomers is adjusted by adding a rich composition for each isomer such that each c9, t11 or t10, c12 contained in the first composition portion is at least 60% of the total octadecanoic ester isomer. Ester compositions can be obtained.
    [27] In a method embodiment of the invention for obtaining a food grade composition suitable for animal feed, food ingredient or human dietary supplement, in an embodiment, the crude CLA-ester with less than 0.5% of phospholipid residue is added to a monovalent such as methyl or ethyl alcohol. Treatment with alkali alcoholate in the presence of low molecular weight alcohol, continued treatment at low temperature (about 90-145 ° C.) until at least 50% of the esters have been converted to CLA-ester, acidified by addition of aqueous acid and then aqueous acid The CLA-esters are separated without distillation from.
    [1] The present invention relates to the field of nutrition of humans and animals, in particular to some novel compositions of conjugated linoleic acid (CLA). This composition is prepared according to a novel method of controlling the isomerization of 9,12-linoleic acid.
    [28] 1 is a flow chart of a process used to prepare a CLA.
    [29] Justice:
    [30] The term "conjugated linoleic acid" or "CLA" as used herein refers to any conjugated linoleic acid or octadecadiene free fatty acid. The term is intended to include and represent both the position and geometric isomers of linoleic acid with two conjugated carbon-carbon double bonds present at any position in the molecule. General linoleic acid differs from general linoleic acid in that it has a double bond at the carbon atoms at positions 9 and 12. Examples of CLA are 2,4-octadecadienoic acid, 4,6-octadecadienoic acid, 6,8-octadecadienoic acid, 7,9-octadecadienoic acid, 8,10-octadecadiene, which are positional isomers Cis- and trans isomers (“E / Z isomers”) of acids, 9,11-octadecadienoic acid, 10,12-octadecadienoic acid and 11,13-octadecadienoic acid. The term "CLA" as used herein includes synthetic and semisynthetic CLA as well as single isomers, selected mixtures of two or more isomers, and unselected mixtures of isomers obtained from natural sources.
    [31] As used herein, the term “triglyceride” of CLA is intended to contain CLA at any of the three positions of triglyceride. Thus, triglycerides containing CLA may contain any of the position and geometric isomers of the CLA.
    [32] As used herein, the term "ester" of a CLA means that any position and geometric isomer of the CLA is physiologically acceptable, including but not limited to, ester linkages, and naturally occurring alcohols (eg, methanol, ethanol, propanol). Is bound to an alcohol or any other chemical group, including). Thus, esters or esterified CLAs of CLA may contain any of the position and geometric isomers of the CLA.
    [33] “Non-naturally occurring isomers” of CLA include, but are not limited to, c11, t13 of octadecadienoic acid; t11, c13; t11, t13; c11, c13; c8, t10; t8, c10; t8, t10; It is intended to include the c8, c10 and trans-trans isomers, and to not contain the t10, c12 and c9, t11 isomers of octadecadienoic acid. "Non-naturally occurring isomers" may also be referred to as "small isomers" of CLA because these isomers are usually produced in small amounts when CLA is synthesized by alkali isomerization.
    [34] As used herein, the term “low impurity” CLA includes free fatty acids, alkylesters and triglycerides, and includes 8,10 octadecadienoic acid, 11,13 octadecadienoic acid and trans-trans octadecadiic acid. CLA compositions containing less than 1% in total are shown.
    [35] "Prepared food product" means any prepackaged food that has been proven suitable for human consumption.
    [36] The term "c" as used herein denotes a chemical bond in the cis direction, and "t" denotes a chemical bond in the trans direction. If the positional isomer of a CLA is indicated without "c" or "t", this indication is intended to include all four possible isomers. For example, 10,12 octadecadienoic acid may be selected from c10, t12; t10, c12; t10, t12 and c10, c12 octadedienoic acid, whereas t10, c12 octadecadenoic acid or CLA represent only a single isomer.
    [37] As used herein, the term “oil” refers to long chain free fatty acids (eg, CLA) or other long chain hydrocarbon groups containing a fluid. Long chain fatty acids include, but are not limited to, various isomers of CLA.
    [38] As used herein, the term "physiologically acceptable carrier" refers to any carrier or excipient commonly used in oily pharmaceuticals. Such carriers or excipients include, but are not limited to, oils, starches, sucrose and lactose.
    [39] As used herein, the term “oral delivery vehicle” refers to any means of oral delivery of a pharmaceutical, including but not limited to capsules, pills, tablets, and syrups.
    [40] As used herein, the term "food" refers to any food or feed suitable for consumption by humans, non-ruminants, or ruminants. A "food" may be a manufactured packaged food (eg mayonnaise, salad dressing, bread or cheese food) or an animal feed (eg extruded and pelleted animal feed or coarse mixed feed).
    [41] The compositions of the present invention are obtained using the preferred starting materials of sunflower or safflower oil in a highly controlled isomerization process. The composition of the present invention has not been obtained so far and is suitable for use on a plant scale because of the production of conjugated linoleic acid through a conventional method for historically entirely different purposes, i. In addition, it is not known whether the content of isomers in the final product is included because the analytical methods for characterizing fatty acids are not widely available.
    [42] In the conventional isomerization process, some of which are still used in more modern forms, the production of conjugated fatty acids is usually carried out at high temperatures above 200 ° C. in aqueous alkali (typically NaOH) at pressures above atmospheric pressure. For example, US Pat. No. 2,350,583 (Bradley) describes an aqueous alkaline process using a treated soap in which both conjugation and polymerization occur under relatively vigorous conditions of 200-250 ° C. for several hours. Fractions of the drying oil were obtained via distillation starting from linseed oil [for similar methods Br. Pat. No. 558.881]. As a variation of this method, US Pat. No. 4,381,264 teaches that a reaction section with low water content (0.5% water) contains a stoichiometric base in the presence of SO 2 to obtain conjugated double bonds of various polyunsaturated fatty acids. have. In US Pat. No. 4,164,505, the aqueous alkali method was applied as a continuous flow method in which the alkali metal hydroxide and water were continuously charged in a flow section maintaining 200 to 370 ° C. At this temperature, the reaction time is very short, but the isomerization is rather poorly controlled. At temperatures above this temperature range, most are expected to be fully converted to double trans species.
    [43] Methods for producing CLA using various non-aqueous solvents and catalysts are described in the literature. Burr describes the use of solvents such as methanol, butanol, ethanol and glycol with various catalysts in US Pat. No. 2,242,230. These reaction parameters are summarized in Table 1 below. All reactions except glycol were carried out at reflux conditions or sealed tubes. These reaction conditions result in inaccurate control of two of the important reaction parameters identified by the inventors, namely temperature and pressure. Inaccurate control of these reaction parameters can lead to incomplete conjugation and formation of undesirable isomers.
    [44] U.S. Patent No. 2,242,230 menstruum catalyst Temperature time ethanol KOH, NaOH Reflux or higher * various Butanol KOH, NaOH Reflux or higher * various Glycol KOH 195 ℃ various Isoamyl alcohol KOH Reflux or higher * various Butanol Tributylamine 140-175 ℃ 22 hours Butanol Potassium acetate 175 ℃ 36 hours Butanol Trisodium phosphate 175 ℃ 36 hours Butanol Potassium phosphate 175 ℃ 36 hours Butanol Sodium benzoate 175 ℃ 36 hours Butanol Potassium thiocyanate 175 ℃ 36 hours Butanol Borax 175 ℃ 36 hours
    [45] Similarly, Baltes et al. Describe the use of non-aqueous solvents and various metallic base catalysts in conjugates of fatty acids in US Pat. No. 3,162,658. The various reaction parameters of the method described in US Pat. No. 3,152,658 are summarized in Table 2 below. U. S. Patent No. 3,152, 658 also describes the use of various low boiling solvents. Since most of these reactions were carried out at temperatures above the boiling point of the solvent used, it is evident that the reaction was carried out under pressure, and pressure is an independent factor influencing the formation of octadecadenoic acid isomers. The product derived from this reaction will therefore contain undesirable isomers.
    [46] U.S. Patent 3,162,658 menstruum catalyst Temperature time Methanol KOH 60-140 ℃ variable Methanol Potassium methylate 140 ℃ variable Butanol Potassium methylate 140 ℃ variable ethanol Potassium methylate 140 ℃ variable Isopropanol Potassium methylate 120-140 ℃ variable Heptane / 3 tert-butanol Potassium butyrate reflux variable Tert-butanol Cesium butyrate 140 ℃ variable Ethylene diamine Potassium methylate 140-160 ℃ variable Methanol Sodium amide 140 ℃ variable
    [47] The CLA of the present invention is almost free of isomers such as the 8,10 isomers, the 11,13 isomers, and the various trans-trans isomers. Such compositions are produced by the precisely controlled non-aqueous alkali isomerization method shown in the flow chart of FIG. 1. Preferably sunflower oil or safflower oil is reacted with excess alkali in an inert gas atmosphere at ambient pressure in a high boiling solvent, ie propylene glycol, at temperatures below the boiling point of this solvent. Under these reaction conditions, accurate control of the temperature (and constant ambient pressure) in the conjugation process is possible. Preferably the alkali is an inorganic alkali such as potassium hydroxide, cesium hydroxide, cesium carbonate, or an organic alkali such as tetraethyl ammonium hydroxide. The catalyst is preferably provided in a 1 molar excess compared to the fatty acid content of the oil. The solvent is propylene glycol. Preferably, the reaction is performed at a temperature of 130 to 165 ° C, more preferably at about 150 ° C. The reaction time may vary, but the reaction for a long time tends to increase the formation of undesirable isomers. A somewhat short reaction time of 2.0 to 6.5 hours proved to be sufficient for excellent yield.
    [48] Those skilled in the art will appreciate that in order to produce the desired composition, the reaction conditions described above may vary depending on the oil, alkali source and device to be conjugated. Preliminary analysis of specific oils indicates whether conditions should be changed to obtain the desired composition. Thus, temperature ranges, pressures and other reaction parameters represent the starting point for each process design and are intended only as a guide. For example, the described temperature range does not include only the range that can be used. It is essential to provide accurate temperature control. However, care must be taken as increasing the pressure may lead to incomplete isomerization and formation of undesirable isomers. Finally, the time of the conjugated reaction can vary. In general, longer reaction times also increase the amount of undesirable isomers formed. Thus, the optimal reaction time is the time at which the reaction is almost or mostly complete but the undesirable isomers are not formed.
    [49] Following the conjugation reaction, the obtained CLA containing composition can be further purified according to FIG. 1. To separate fatty acids from the conjugated reaction mixture, the reaction mixture is cooled to approximately 95 ° C., an excess of 50 ° C. is added, and the mixture is slowly stirred while the temperature drops to about 50 ° C. to 60 ° C. Fatty acid soap is formed while water is added, and glycerol is formed as a byproduct. Subsequently, a molar excess of concentrated HCl is added while stirring. Then, the aqueous and nonaqueous layers are allowed to separate at about 80-90 ° C. Drain the bottom layer containing water and propylene glycol. The remaining propylene glycol is removed by vacuum dehydration at 60-80 ° C.
    [50] The dried CLA composition can then be degassed in a degassing unit equipped with a cold trap, to remove all residual propylene glycol. The CLA is then distilled in a molecular distillation apparatus at 190 ° C. under vacuum (10 −1 to 10 −3 mbar). The advantage of this purification system is that the time the CLA is held at elevated temperature is short (less than 1 minute). Conventional batch distillation procedures must be avoided by far as they are carried out for several hours at a temperature elevated to approximately 180-200 ° C. At such elevated temperatures, undesirable trans-trans isomers will form. Approximately 90% of the feed material is recovered as a slightly yellow distillate. The CLA may then be deodorized by heating to about 120 ° C. to 170 ° C., preferably about 150 ° C. for 2 hours to improve odor and taste. Excessive heating can lead to the formation of trans-trans isomers. This process produces a CLA composition having a solvent level of less than about 5 ppm, preferably less than about 1 ppm. This method removes trace amounts of toxic solvents such that there is little toxic solvent residue in the composition obtained.
    [51] The method described above is readily applicable to pilot and commercial scale. For example, 400 kg safflower oil can be conjugated at 150 ° C. for 5 hours by adding 200 kg of KOH as catalyst in 400 kg of propylene glycol. The obtained CLA can be purified as described above. In addition, commercial scale batch systems can be readily modified to produce the desired CLA composition. For example, stainless steel reactors should preferably be lined with glass to prevent corrosion due to pH levels below 3.0. It should be borne in mind, however, that conjugation methods using non-aqueous solvents are generally less corrosive than those performed with water.
    [52] Preferred oils for conjugation are sunflower and safflower oils. Compared with soybean oils, these oils have low concentrations of undesirable components such as phospholipids and sterols. Such undesirable components can cause gum and other undesirable polymer formation which will contaminate the conjugation device. The various properties of these oils are summarized in Tables 3, 4 and 5 below.
    [53] Comparison of Contaminants
    [54] Phospholipids Big head 1.5-3.0% sunflower 0.4-1% sunflower 0.4-1%
    [55] Sterols,% * non-saponifiable Big head sunflower Safflower Campestrol 20 * Campestrol 8 Campestrol 13 Stigmasterol 20 Stigmasterol 8 Stigmasterol 9 β-stosterol 53 β-stosterol 60 β-stosterol 52 Δ 5 avensterol 3 Δ 5 avensterol 4 Δ 5 avensterol 1 Δ 7 stigmasterol 3 Δ 7 stigmasterol 15 Δ 7 stigmasterol 15 Δ 7 avenasterol 1 Δ 7 avenasterol 4 Δ 7 avenasterol 3 0.36% total in oil 0.36% total in oil 0.36% total in oil * May not be 100.
    [56] Big head sunflower Safflower Iodine levels 134.6 135.4 143.6 Saponification figures 190.7 190.6 190.3 Saponification 0.6 0.7 0.6
    [57] In the examples which follow, some comparative experiments were conducted to highlight important features of the CLA compositions of the present invention under non-optimal conditions or compared to those prepared according to the aqueous alkali methods of the prior art. In Example 1, CLA was prepared by the method of the present invention. In Example 2, CLA was prepared by conventional aqueous alkali method. In Example 3, the reaction of Example 1 was repeated in almost the same manner except for the high temperature. Finally, in Example 4, the aqueous alkali reaction substantially the same as that of Example 2 was performed at low temperature. The exact conditions and details of each experiment are described in the Examples section below. Analytical profiles of CLA isomer content are listed in Tables 1-4.
    [58] Referring to the data in Table 5, the relative area% for each identified peak corresponding to the individual isomers for each of the four experiments is obtained. GC plots yield several peaks of each test sample. The total value is obtained by integrating the area of each of these peaks. The identification of the peak was determined according to its relative position using an illustration of the standard elution profile and the scientific literature. The top row shows the residual values of the nonconjugated starting material, 9,12-linoleic acid. Low and high temperature reactions in propylene glycol resulted in very high conversions of over 99% of the starting materials.
    [59] Referring to the first row, unlike any of the control compositions in Example 1, a peak corresponding to a mixture of 11,13 isomers, specifically a peak corresponding to c11, c13, a peak corresponding to any 8,10 isomer It is apparent that the peaks of, and unidentified isomers disappear completely. In the case of the c9, t11 isomer, the peaks of the 8,10 and 9,11 isomers in the GC overlap and are split here by excluding portions of the peaks identified as 8,10 through NMR studies only for the material of Example 1 do. This was not done in other experiments, so for Examples 2-4 the three columns are the combined values of 8,10 and 9,11. In general, 8,10; For 11,13 and unidentified isomers, undetectable low values of less than 1% are therapeutic and nutritional values, which trace traces of potentially contaminants, particularly those suspected of having absorption pathways in lipogenesis. This is because the value decreases to the level. In non-ruminant animals, for example, adding 0.25-2.5% of CLA to food can increase the incidence of CLA in tissues to a level similar to that found in ruminants, thus providing a mixed isomer of CLA that is not present in other animals. It can be a source.
    [60] Example 2 provides a method representative of the typical aqueous alkali product of CLA prepared by conventional methods. Overall, also the conversion is not effective in the production of the c9, t11 and t10, c12 isomers. It should also be noted that a high percentage of suspected 11,13 isomers and a significant percentage of unidentified material.
    [61] Example 3 shows the importance of the temperature parameter. The rise in temperature in the propylene glycol medium dramatically increases the amount of contaminating isomers instead of the c9, t11 and t10, c12 isomers. It is also interesting to note that there is a sharp increase in trans and trans species at high temperatures because double bond rearrangements favorably occur at higher energy stresses resulting in more stable electron placement.
    [62] Example 4 shows that lowering the temperature in an aqueous alkaline system substantially reduces the amount of some contaminating isomers. However, yields are drastically reduced, and the numbers in the 11,13 isomer group are still high, suggesting that the formation of these electron batches is more affected by the action of bases in the aqueous medium than is explained by the total kinetic energy in the system. do. It should also be noted that a very long reaction time of 22.5 hours, which is too long for an efficient plant scale batch process.
    [63] Table 6 simply converts the percentage of relative isomers as a function of peak area in the various reactions to the corresponding peak ratios. The process of the invention virtually completely converts 9,12-linoleic acid to two desired CLA isomers of approximately equal amounts. At high temperatures, the generation of 11,13 isomers is still less than one third of that of the low temperature aqueous alkali process, even if performed in propylene glycol.
    [64] In some embodiments, the present invention also provides a method of preparing an alkyl ester of CLA. After fat separation and dehydration, the free fatty acid is mixed with methanol or monovalent low molecular weight alcohol and heated to the boiling temperature of the alcohol. Under reflux conditions, esterification was performed while removing the water generated in the reaction through a condenser. After adding an additional amount of monovalent alcohol equal to or different from the alcohol, the alcoholate catalyst was blended into the ester mixture. Typical alcoholate catalysts are sodium or potassium ethoxide, sodium or potassium methoxide, sodium or potassium butoxide, or sodium potassium propoxide.
    [65] In esterification, other branched or straight-chain monohydric alcohols may also be used but methanol or ethanol is preferred. Longer aliphatic alkyl groups are more fatty compatible substances. Viscosity also tends to increase. Using products of varying viscosity to suit different types of feeds or foods with different consistency, the desired fluidity or formulation properties can be achieved without affecting the therapeutic or nutritional properties caused by CLA residues. . The theory and experiment of esterification is conventional. A basic description of the most common methods is described in McCraw-Hill Encyclopedia of Science & Technology, McGraw-Hill Book Co., N.Y .; 1996 (5th ed.). There are a variety of esterases in the body of animals and humans to break down CLA-esters and thus release free fatty acids easily. Tissue uptake can have different rates depending on the tissue involved and the benefits sought.
    [66] In the isomerization step, it has been found that the alcoholate catalyst produces a much better product than the aqueous alkali mediated isomerization. Aqueous alkali mediated isomerization always produced undesirable isomers even under mild reaction conditions. Mild conditions reduced the amount of undesired isomers, but yields decreased significantly as shown in the examples. In most systems, the appearance of the c9, t11 and t10, c12 isomers prevails, and they are formed in approximately equal molar amounts. Until now, it was impossible to control the isomerization of one isomer that excluded the other. It is desirable to increase the percentage of one isomer or the other isomer (depending on the physiological effect to be achieved), but at present this should be done in large quantities by adding a source rich in the desired isomer.
    [67] The present invention contemplates the use of purely prepared derivatives of CLA. For example, CLA may be free or bound via ester linkages, or may be provided in the form of an oil containing CLA triglycerides as described in Examples 5 and 6. In such embodiments, the triglycerides may comprise CLA partially or wholly conjugated to the glycerol backbone. The CLA may preferably be provided as methyl ester or ethyl ester as described in Examples 8 and 9. The CLA may also be in the form of non-toxic salts such as potassium or sodium salts, such as potassium salts or sodium salts (e.g., salts formed by reacting a chemical equivalent amount of free acid with an alkali hydroxide of pH about 8-9).
    [68] In one embodiment of the invention, the novel triacylglycerols are synthesized comprising the novel CLA isomer mixtures described below for the non-aqueous isomerization of linoleic acid obtained from sunflower and / or safflower oil. Very rich CLA (90-96%) pure triacylglycerols can be identified by H NMR. The esterification is carried out using immobilized Candida antarctica lipolytic enzymes. Preferably the CLA comprises at least 40%, and above 45 to 48% of c9, t11-octadecadienoic acid and t10, c12-octadecadienoic acid and mixtures thereof. 8,10; 11,13 and trans, trans ester isomers are present in less than 1%, or less than 5% of the total. In addition, the resulting triacylglycerols are not purified to remove phospholipids and sterol residues. However, these figures remaining in the isomerization of sunflower and safflower oils are suitable for commercial applications requiring safe and edible products in the feed and food sectors.
    [69] The immobilized Candida antarctica lipase will be used in a manner similar to that described by Harraldson et al. For polyunsaturated fatty acids of the n-3 type. The esterification reaction was carried out at 50 to 75 ° C., preferably at 65 ° C., without any solvent, and the water or alcohol produced together during ester formation was separated off (from the ester) by vacuum treatment. This allows the triacylglycerol formation to be completed and to obtain a high purity product free of virtually any mono- and diacylglycerols in substantially quantitative yield. The free fatty acids can be used in stoichiometric amounts, ie 3 molar equivalents based on glycerol or 1 molar equivalents based on the molar equivalent number of hydroxyl groups present in the glycerol residues. Lipolytic enzymes require only 10% dosage based on the total weight of the substrate, which can be used multiple times. This is very important in terms of productivity. All of these, together with the fact that no solvent is required, allow for the reduction and enlarging of the volume, thus making the method of the present invention a high possibility in terms of mass and plantation. In addition, a slight excess of (<5/5) free fatty acids can be used to speed up the reaction towards termination and ensure the completion of the reaction.
    [70] At the beginning of the reaction, 1- or 3-mono-acylglycerides are formed first, followed by reaction of 1,3-diacylglycerides, and finally for a long time, to form triglycerides. Mono- and diacylglycerides are useful intermediates in that they exhibit biological activity, are highly soluble in an aqueous cellular environment and may be involved in other molecular synthesis pathways such as the synthesis of phospholipids or other functional lipids. Triglycerides, on the other hand, are often deposited intact on cell membranes or storage vesicles. Thus, administration of CLA in mono-, di- or triglycerol form rather than free fatty acids or esters may be effective in the mode of absorption and distribution, the rate of metabolism and the structural or physiological role of the CLA component.
    [71] In one preferred embodiment oral administration is performed. CLA may be formulated into tablets, pills, dragees, capsules, solutions, solutions, slurries, suspensions and emulsifiers with starch, sucrose or lactose. The CLA may be provided in an aqueous solution, oily solution or any of the other forms discussed above. Tablets and capsules of the present invention may be coated with enteric skin that dissolves at a pH of about 6.0 to 7.0. A suitable enteric coating that dissolves in the small intestine but does not dissolve in the stomach is cellulose acetate phthalate. In some embodiments, the CLA is provided in soft gelatin capsules (Tonalin ™ ) containing 750 mg of 80% CLA. CLA may be provided by any of several routes, including but not limited to intravenous, intramuscular, intraarterial, spinal, intradural, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal methods. Can be. Details of additional formulation and administration techniques can be found in Remington's Pharmaceutical Sciences, Maack Publishing Co., Easton, PA.
    [72] Effective amounts of CLA can be provided as adjuvants in various manufactured foods and beverages. For the purpose of this use, manufactured food means natural, processed, dietary or non-dietary foods to which CLA has been added. CLA can be added in the form of free fatty acids, or as an oil that partially or wholly contains the triglycerides of CLA. Thus, CLA is not limited to dietary beverages, diet bars, supplements, manufactured frozen wheat, candy, snack products (eg chips), manufactured meat products, milk, cheese, yogurt and other fats. Or directly into various manufactured foods, including oil containing foods.
    [73] CLA is sensitive to oxidation. Thus, for human use, it is desirable to package CLA with a suitable antioxidant such as lecithin, tocopherol, ascorbate, ascorbyl palmitate, or a spice extract such as rosemary extract.
    [74] <Example 1>
    [75] Isomerization of Safflower Oil with Propylene Glycol at Low Temperature
    [76] Safflower oil isomerized in propylene glycol at low temperature using KOH as catalyst. The isomerization instrument consisted of a two-neck flask with a thermometer located in one neck, with a small opening to reduce overpressure. Another neck of the flask was fitted with a nitrogen supply. The solution added to the flask was stirred using a magnetic rod and a magnetic stirrer. The temperature of the flask was controlled by placing the flask in a thermostat-controlled oil bath placed on a magnetic stirrer.
    [77] The flask was charged with 60.27 g of propylene glycol and 28.20 g of KOH and immersed in an oil bath. The temperature was increased to 130 ° C. to dissolve KOH. After KOH dissolved, 60.09 g safflower oil was introduced into the flask. High volume nitrogen was circulated through a two necked flask for 5 minutes and then reduced to low volume. The mixture was heated to 150 ° C. and took about 40 minutes. Thereafter, the mixture was reacted at 150 ° C. for 3.5 hours. At regular intervals, 3 ml of sample was withdrawn for analysis.
    [78] The sample was placed directly in 6 ml of hot water and excess citric acid was added until the free fatty acid separated as the top layer. Heating was necessary to prevent solidification while adding citric acid. To convert free fatty acids to methyl esters for gas chromatography analysis, 0.025 g of free fatty acids, 5 ml of 4% HCl solution and ethanol were added to the test tube. After nitrogen was added to the test tube, the test tube was sealed and placed in a 60 ° C. water bath for 20 minutes. The test tube was then cooled and 1 ml of purified water and 5 ml of isooctane were added. Nitrogen was added to the test tube and the test tube was shaken for 30 seconds. The resulting top layer was added to 1 μl of purified water in fresh test tubes and shaken again under nitrogen. The resulting top layer was then washed with isooctane and decanted into a third test tube. A small amount of sodium sulfate was added for water absorption. Thereafter, 1 μl of the sample was injected directly into the gas chromatograph.
    [79] Gas chromatography conditions were as follows:
    [80] System: Perkins-Elmer Auto System
    [81] Injector: No separation at 240 ° C
    [82] Detector: flame ionization detector at 280 ° C
    [83] Carrier: Helium
    [84] Column: WCOT Fused Silica 0.25 mm X100M, CP-SL 88 for FAME, DF 0.2
    [85] Oven program: increase from 80 ° C. (0 min) to 220 ° C. at 10 ° C./min and hold at 220 ° C. for 10 minutes.
    [86] All results are expressed as relative peak area percentages. Standard materials are generally not commercially available, so eluted peaks have been demonstrated with other systems. GC-MS measures the number of cis and trans bonds but not the position. Thus, NMR analysis was used to verify binding sites. Main peaks were c9, t11 and t10, c12. For NMR analysis of CLA isomers, see Marcel S. F. Lie Ken Jie and J. Mustafa, Lipids, 32 (10) 1019-34, 1997, which is incorporated herein by reference.
    [87] The data shown in Table 6 below and summarized in Table 10 below indicate that isomerization of safflower oil using polypropylene glycol as solvent, KOH as catalyst and low temperature yields conjugated linoleic acid free of 8,10 and 11,13 isomers. Proved. The highly polar columns used in this experiment were used to successfully separate the 8,10 and 11,3 isomers from the c9, t11 and t10, c12 isomers. The 8,10 isomers tend to elute together or immediately after the c9, t11 isomer. The 11,13 isomer elutes before the t10, c11 isomer or together with the t10, c12 isomer depending on column conditions.
    [88] Conjugated linoleic acid was prepared according to the above method, characterized by comparing the various isomers produced. First, the isomerization reaction was essentially complete. Completion of the reaction is obtained by dividing the peak area by subtracting the residual c9, t12 linoleic acid from the linoleic acid isomer by the total peak area. This value was 0.994. Second, the ratio of the c9, t11 and t10, c12 isomeric peak areas to the total peak area can be determined. This value was 0.953. Third, the ratio of the t9, t11 and t10, t12 isomers to the c9, t11 and t10, c12 isomers can be determined. This value was 0.010. Fourth, the ratio of t9, t11 and t10, t12 isomeric peak areas to the total peak area can be determined. This value was 0.009. Fifth, the ratio of the t10, t12 isomer to the c9, t11 isomer can be determined. This value was 1.018. These ratios are summarized in Table 11 below.
    [89] <Example 2>
    [90] Aqueous Isomerization at High and High Pressures
    [91] 50 g of water and 25.32 g of NaOH were added to a high pressure reactor (Parr Model 450 ML Benchtop Alloy 400 with pressure gauge and stirrer). NaOH was dissolved and 94.0 g safflower oil were added to the reactor. After closing the reactor and flushing with nitrogen for 2 minutes, all valves were closed. The reactor was heated to 210 ° C. in an electric gasket and held at this temperature for 6 hours. The temperature was then reduced to 60 ° C., then the pressure was lowered and the reactor opened. 2 g of the resulting solidified salt were removed from the reactor and dissolved in water at about 40 ° C. Citric acid was then added to reduce the pH of the solution to less than 6. Samples were withdrawn from the fatty acid top layer and prepared for gas chromatography as in Example 1.
    [92] The results of the gas chromatography are shown in Table 7 and summarized in Table 10. These data indicate that the isomerization method forms relatively high amounts of the 8,10 and 11,13 isomers. The ratios are shown in Table 11.
    [93] <Example 3>
    [94] Non-Aqueous Alkali Isomerization of Safflower Oil at High Temperature and High Pressure
    [95] 100.48 g of propylene glycol and 46.75 g of KOH were added to the high pressure reactor as in Example 2. The reactor was then heated to 130 ° C. to dissolve KOH. Then 100.12 g safflower oil was added to the KOH-propylene glycol mixture. After closing the reactor and flushing with nitrogen for 1 minute, all valves were closed. The reactor was then heated to 210 ° C. and maintained at this temperature for 1 hour. The reactor was cooled and the contents decanted into 120 g of hot water. While stirring, 35.3 g 37% HCl and 27.59 g citric acid were added successively to the fatty acid. Samples were withdrawn from the top layer and dried in a vacuum flask at 60 ° C. The resulting fatty acid sample was analyzed by gas chromatography as in Example 1.
    [96] The results are shown in Table 8 below and summarized in Table 10. This experiment demonstrated that isomerization of safflower oil at high temperature with KOH and non-aqueous solvent produced a significant amount of the 8,10 and 11,13 isomers and the t9, t11 and t10, t12 isomers. The ratios are shown in Table 11.
    [97] <Example 4>
    [98] Aqueous alkali reaction at low temperature
    [99] 49.94 g of water and 39.96 g of NaOH were added to the high pressure reactor as in Example 3. The mixture was heated until NaOH dissolved. Thereafter, 100.54 g of safflower oil was added to the high pressure reactor, the reactor was flushed with nitrogen, and all valves were closed. The high pressure reactor was heated to 179 ° C. for 22.5 hours. Samples were prepared for gas chromatography as in Example 3. The data is shown in Table 9 below and summarized in Table 10. This experiment demonstrates that no conjugated reactions are achieved when low temperatures are used for aqueous alkali isomerization. In addition, significant amounts of the 8,10 and 11,13 isomers were prepared. The ratios are shown in Table 11 below.
    [100]
    [101]
    [102]
    [103]
    [104]
    [105]
    [106]
    [107]
    [108]
    [109] Example 5
    [110] Preparation of Triacylglycerols of CLA by Direct Esterification
    [111] Typical H nuclear magnetic resonance spectra were recorded on a Bruker AC 250 NMR spectrometer in deuterated chloroform as solvent. PrepLC® system 500A using PrepPak® 500 / silica cartridge column (Millipore) eluting with 10% diethyl ether in petroleum ether HLPC separation was performed. As described in Haraldsson, et al., Acta Chem Scanned 45, 723 (1991), GLC analysis was performed on Perkins-Elmer 8140 gas chromatography following the procedure described above.
    [112] Unfluided Candida antarctica lipase was purchased from Novo Nordisk as Novozyme ™. This was used directly in the esterification experiment. Analytical grade diethyl ether purchased from Merck was used without any purification, but also synthetic grade n-hexane from Merck was freshly distilled prior to use in extraction and HPLC chromatography. Glycerol (99%) was purchased from Sigma and Aldrich Chemical Company and used without further purification. CLA concentrate was purchased from Natural Lipids, Norway, as a free fatty acid of Tonalin ™. Its purity was confirmed by GLC analysis and high-field NMR spectroscopy showing some glyceride impurities. As measured by GLC at the Science Institute, CLA concentrates showed 43.3% of 9-cis, 11-trans-linoleic acid, 44.5% of 10-trans, 12-cis-linoleic acid, and 5.4% of other CLA isomers. , 5.6% oleic acid and 0.6% palmitic acid and stearic acid, respectively.
    [113] <Example 6>
    [114] Preparation of Triacylglycerols of CLA by Direct Esterification
    [115] Unflowed Candida antartica lipase (1.25 g) was added to a mixture of glycerol (1.22 g, 13.3 mmol) and CLA (molecular weight 280.3 g / mol; 11.6 g, 41.5 mmol) as free fatty acid. The mixture was slowly stirred on a magnetic stirrer hot plate at 65 ° C. under continuous vacuum of 0.01-0.5 Torr. Volatile water generated during the reaction was continuously condensed in a liquid nitrogen cooling trap. After 48 hours, the reaction was stopped, n-hexane was added and the enzyme was separated by filtration. The organic phase was treated with an aqueous alkaline solution of sodium carbonate to remove excess free fatty acid (if necessary). The organic solvent (after drying over anhydrous magnesium sulfate, if appropriate) was removed on a rotary evaporator under vacuum, then subjected to a high vacuum to actually give a slightly yellowish oil (10.9 g, average molecular weight 878.6 g / mol; 93% yield). Pure product was obtained. When using stoichiometric amounts of free fatty acids, titration with standardized sodium hydroxide was used to determine the free fatty acid content of the crude reaction product (corresponding to a content of at least 99% equivalent to a triglyceride content of at least 97%, Free fatty acid content of less than 1% based on the number of moles of ester groups). The crude product was introduced directly into HPLC eluting with 10% diethyl ether in n-hexane to give 100% pure triglycerides as a colorless oil.
    [116]
    [117] Samples were collected regularly as the reaction progressed to monitor the extent of the reaction and provide details on the composition of the individual glycerides during the reaction. Samples were analyzed by HNMR spectroscopy and provided a good analysis of the composition of mono-, di- and triacylglycerols during the reaction. The results are shown in Table 12 below. As can be seen from the table, 1,3-diacylglycerol dominated the reaction mixture during the first two hours of the reaction. After 4 hours, triacylglycerols were dominant, reaching 98% composition after 22 hours and 100% composition after 48 hours. As expected, 1,2-diacylglycerol was significantly lower than 1,3-diacylglycerol. While 1-monoacylglycerol reached its maximum during the first hour of the reaction, 2-monoacylglycerol was not detected throughout the reaction.
    [118]
    [119] <Example 7>
    [120] Effect of Temperature and Reaction Time on CLA Yield and Composition
    [121] The effect of temperature and reaction time on the conjugation of safflower oil was measured. Water and NaOH were added to a high pressure reactor (Far Model 450 ML Benchtop Alloy 400, equipped with pressure gauge and stirrer) as shown in rows 1 and 2 of Table 1. NaOH was dissolved and safflower oil (3 rows) was added to the reactor. After closing the reactor and flushing with nitrogen for 2 minutes, all valves were closed. The reactor was heated to the desired temperature (4 rows) in an electrical gasket and maintained at this temperature for the desired time (5 rows). The temperature was then reduced to 60 ° C., then the pressure was lowered and the reactor opened. For each reaction, 2 g of the resulting solidified salt was removed from the reactor and dissolved in water at about 40 ° C. Citric acid was then added to reduce the pH of the solution to less than 6. Samples were withdrawn from the fatty acid top layer and prepared for gas chromatography.
    [122] The results of the gas chromatography are shown in columns 6 (total percentage of 9,11 and 10,12 isomers), column 7 (total percentage of 11,13 isomers) and column 8 (total percentage or yield of all CLA isomers). These data indicate that the total amount of conjugation and the percentage of 11,13 isomers increase with increasing reaction time and temperature. Under conditions of low formation of the 11,13 isomer, the total amount of conjugated was also low.
    [123]
    [124] <Example 8>
    [125] Conjugation of Safflower Fatty Acid Methyl Ester (FAME)
    [126] The reaction was carried out in a closed vessel. The following components were mixed together: a mixture of 100 g safflower FAME and approximately 2.8 g KOCH 3 and 2.8 g methanol. There was probably more KOMe than methanol due to the evaporation of methanol while mixing the two components. The mixture was stirred for 5 h at 111-115 ° C. under a nitrogen atmosphere in a sealed reaction vessel. The distribution of isomers was analyzed by gas chromatography. The results are summarized in Table 2. Untreated GC data is shown in Table 3. These data indicate that conjugation of safflower FAME is carried out under mild conditions to produce a product that does not contain the desired amounts of undesired 8,10 and 11,13 isomers.
    [127]
    [128] Example 9
    [129] Large-scale batch production of conjugated safflower FAME
    [130] Preparation of safflower conjugated FAMEs could be divided into two stages, methanolysis and conjugation. For methanolysis, 6,000 kg of safflower oil were placed in a closed reactor. The reactor was purged with nitrogen at atmospheric pressure and 1150 liters of methanol and 160 kg of NaOCH 3 (30% solution) were added. The mixture was stirred while heating to 65 ° C. and reacted at 65 ° C. for 2 hours. The resulting bottom layer was decanted while purging the reactor with nitrogen gas. Then 1000 liters of water (40-50 ° C., dissolving 50 kg of citric acid monohydrate) were added with stirring. The layers were separated (about 60 minutes) and the bottom layer was decanted while purging the reactor with nitrogen gas. The resulting safflower FAME product was dried at 80 ° C. under vacuum for 1 hour.
    [131] To conjugate the safflower FAME, 250 kg of KOCH 3 , dissolved in methanol to form a paste, was added to the reactor. Thereafter, the mixture was heated to 120 ° C. while stirring, and the reaction was continued for 3 hours. The reaction was cooled to 100 ° C. and 1000 liters of water (40-50 ° C., dissolving 50 kg of citric acid monohydrate) were added with stirring. After the mixture was stirred for 15 minutes, the layers were separated for 20 minutes. The bottom layer was decanted and the product dried at 80 ° C. for 1 hour and then stored under nitrogen.
    [132] The resulting CLA was analyzed using Perkin Elmer Automated XL GC under the following conditions:
    [133] Column: WCOT Fused Silica 100 m × 0.25 mm, Coated CP SIL 88
    [134] Carrier: He gas, 30.0 psi
    [135] Temperature: 220 ℃
    [136] Run time: 35 to 90 minutes
    [137] Injector: No separation at 240 ° C
    [138] Detector: Flame Ionization Detector (FID) at 280 ° C
    [139] GC results are summarized in Tables 15 and 16 below.
    [140]
    [141]
    [142]
    [143] The following are examples of conventional animal foods containing CLA free fatty acids, triglycerides and esters of the invention.
    [144] <Example 10>
    [145] A. Food at the start of pig development
    [146] ingredientlbkg Corn, Yellow (8.4% Protein)1067484.7 Soybean meal, solvent extracted, unpeeled (47% protein)570259 CLA52.3 Whey, Dried (12.0% Protein)300136 Dicalcium phosphate2411 Limestone167 Iodine Flame52 Trace mineral premixes52 Vitamin Fricmix84 gun2000908
    [147] B. Food for growth-deadline for pigs (manufactured from 40-240 LBS [18-109 KGS])
    [148] ingredientlbkg Corn, Yellow (8.4% Protein)1566Soybean meal, solvent extracted (44% protein)380CLA5Dicalcium phosphate21Limestone15Iodine Flame5Trace Mineral Premix3Vitamin Fricmix3gun2000
    [149] C. Pig-growth food (produced from pig 121-240 LBS [55-109KGS])
    [150] ingredientlbkg Corn, Yellow (8.4% Protein)1687Soybean meal, solvent extracted (44% protein)265CLA5Dicalcium phosphate18Limestone15Iodine Flame5Trace Mineral Premix2Vitamin Fricmix3gun2000
    [151] Composition and Analysis of Trace Mineral Premixes for Pigs
    [152] elementSourceAmount (lb) Copper (Cu)Copper sulfate1.500 Iodine (I)Potassium Iodide0.010 FeFerrous sulfate25.000 Manganese (Mn)Manganese sulfate2.500 Selenium (Se)Sodium selenite0.025 Zinc (Zn)Zinc sulfate25.000carrier45.965 gun 100.000
    [153] Composition of Vitamin Premix for Pigs
    [154] vitaminamount Essential ingredientsVitamin A (Million IU)5.0 Vitamin D (Million IU)0.6 Vitamin E (1,000 IU)26.0 Niacin (g)25.0 d-pantothenic acid (g)20.0 Riboflavin (g)6.0 Vitamin B-12 (mg)25.0 Random ingredientBiotin (g)0.3 Menadione (g)4.0 carrierVolume up to 10 lb gun10.0
    [155] D. 18% Protein Layer Food for Hens
    [156] ingredientlbkg Crushed Yellow Corn1242564.5 CLA52.3 Alfalfa feed, 17%2511.3 Soybean feed, not peeled451.6205.3 Meat and Bone Feed (47%)5023.0 DL-Methionine1.00.5 Dicalcium phosphate73.1 Crushed limestone17479.1 Iodine Flame73.1 Stabilized yellow grease3717.2 Mineral and Vitamin Supplements Calcium Pantothenate (mg)5,000Manganese (g)52Selenium (mg)90.8Zinc (g)16Vitamin A (IU)6,000,000Vitamin D 3 (IU)2,000,000Choline (mg)274,000Niacin (mg)12,000Riboflavin (mg)2,000Vitamin B-126gun2000909.4
    [157] E. Food at the beginning and end of chicken development
    [158] ingredientDevelopment starts (up to 24 days)Deadline (25 days until market) lbkglbkg Crushed Yellow Corn1,1065031235561 CLA-ester52.352.3 Soybean feed, not peeled605275420191 Alfalfa feed, 17%--2511 Corn Gluten Feed, 60%50237534 Fish feed, herring, 65%50235023 Meat and Bone Feed, 47%50235023 Dicalcium phosphate10494 Crushed limestone167146.3 DL-Methionine0.80.3-- Stabilized yellow grease10145.711049.4 Iodine Flame7373 Mineral and Vitamin Supplements Calcium Pantothenate (mg)5,000 5,000Manganese (g)75 75Organic Arsenic Supplements0.1 0.1Selenium (mg)90.8 90.8Zinc (g)30 30Vitamin A (IU)4,000,000 4,000,000Vitamin D (IU)1,000,000 1,000,000Vitamin E (mg)2,000 2,000Vitamin K (mg)2,000 2,000Choline (mg)503,000 672,000Niacin (mg)20,000 20,000Riboflavin (mg)3,000 3,000Vitamin B-12 (mg)12 12gun2000.9909.32000.1909.5
    [159] F. Turkey Food at Growth / Finishing
    [160] ingredientGrowth (8-16 weeks)Deadline (from 16 weeks to market) lbkglbkg Crushed Yellow Corn11945951490677.2 Wheat secondary5023-- Alfalfa feed, 17%2511.32511.3 Soybean feed, not peeled570259335152.3 Meat and Bone Feed, 47%50235023 Dicalcium phosphate3214.52310.5 Crushed limestone146178 Stabilized yellow grease4520.74520.7 CLA-ester52.352.3 Iodine Flame104.5104.5 Mineral and Vitamin Supplements Calcium Pantothenate (mg)4,500 4,500Manganese (g)30 30Selenium (mg)181.6 181.6Zinc (g)30 30Vitamin (IU)1,500,000 7,500,000Vitamin D (IU)1,700,000 1,700,000Vitamin E (IU)10,000 10,000Biotin (mg)100 100Choline (mg)388,000 417,000Niacin (mg)46,000 48,000Riboflavin (mg)5,000 5,000Vitamin B-126 6gun2000909.32000909.3
    [161] G. Dry Food Composition for Dogs
    [162] ingredientComposition 1,%Composition 2,% Meat and Bone Feed, 50% CP8.015.0 Fish Feed, 60% CP, Low Fat5.03.0 Soybean Feed, 44% CP12.0- Soybean Feed, 50% CP-19.0 Wheat germ feed, 25% CP8.05.0 Skim milk, dried4.02.75 Grains, Mixed51.23- Corn Flakes-23.25 Wheat bran4.0- Wheat Flakes-23.35 Animal fat1.752.75 CLA-ester0.250.25 Steamed Bone Feed2.0- Brewer's Yeast2.05.0 Fermentable Soluble, Dehydrated1.0- Salts and trace minerals0.50.5 Vitamin mixtures0.250.25 Iron oxide0.02- gun100.00100.00
    [163] H. Dog Semi-Wet Food Composition
    [164] ingredientComposition 1,%Composition 2,% Soy flakes30.933.5 Meat By-Product, 70% Moisture32.0- Meat and Bone Feed, Dehydrated-7.3 water-25.6 Party21.021.0 Calcium and Phosphorus Supplements3.3- Soybean husk3.13.1 Skim milk, dried2.5- Propylene glycol2.12.1 Sorbitol2.02.0 Animal fat0.753.95 CLA-ester0.250.25 Emulsifier0.9- Potassium sorbate0.350.35 salt0.60.6 vitamin0.250.25 gun100.000100.000
    权利要求:
    Claims (30)
    [1" claim-type="Currently amended] A composition containing 50% or more of conjugated linoleic acid, characterized in that it comprises less than 1% of octadecadenoic acid isomers produced non-naturally.
    [2" claim-type="Currently amended] The composition of claim 1, which contains less than 1% of the 11,13-octadecadienoic acid isomer and the trans-trans octadecadienoic acid isomer.
    [3" claim-type="Currently amended] The composition of claim 1 containing less than 1% of the 8,10-octadecadienoic acid isomer and the trans-trans octadecadienoic acid isomer.
    [4" claim-type="Currently amended] The composition of claim 1 wherein the total content of t9, t11-octadecadienoic acid and t10, t12-octadecadienoic acid is less than 1%.
    [5" claim-type="Currently amended] 5. The composition of claim 1, wherein the composition is an isomerized commercial seed oil.
    [6" claim-type="Currently amended] 6. The composition of claim 5, wherein said seed oil is selected from the group consisting of sunflower oil and safflower oil.
    [7" claim-type="Currently amended] at least about 30% t10, c12 octadecadienoic acid, at least about 30% c9, t11 octadecadienoic acid, and 8,10 octadecadienoic acid, 11,13 octadecadienoic acid and trans-transoctadecadiic acid A biologically active conjugated linoleic acid composition comprising a mixture of free fatty acid conjugated linoleic acid isomers comprising less than about 1% total.
    [8" claim-type="Currently amended] 8. The composition of claim 7, further comprising a food in which the t10, c12 octadecadienoic acid is mixed.
    [9" claim-type="Currently amended] The composition of claim 8 wherein the food is for human consumption.
    [10" claim-type="Currently amended] The composition of claim 8 wherein the food is a feed prepared for animal consumption.
    [11" claim-type="Currently amended] At least about 30% of t10, c12 octadecadienoic acid, at least about 30% of c9, t11 octadecadienoic acid at positions R 1 , R 2 and R 3 , and 8, A biologically active acylglycerol composition comprising less than about 1% total 10 octadecadienoic acid, 11,13 octadecadienoic acid and trans-trans octadecadienoic acid.

    Where
    R 1 , R 2 and R 3 are selected from the group consisting of hydroxyl groups and octadecadienoic acid.
    [12" claim-type="Currently amended] The composition of claim 11, further comprising a food in which the t10, c12 octadecadienoic acid is mixed.
    [13" claim-type="Currently amended] The composition of claim 12, wherein the food is for human consumption.
    [14" claim-type="Currently amended] The composition of claim 12, wherein the food is a feed prepared for animal consumption.
    [15" claim-type="Currently amended] at least about 30% t10, c12 octadecadienoic acid, at least about 30% c9, t11 octadecadienoic acid, and 8,10 octadecadienoic acid, 11,13 octadecadienoic acid and trans-transoctadecadiic acid A biologically active conjugated linoleic acid composition comprising a mixture of isomers of conjugated linoleic acid esters comprising less than about 1% of the total.
    [16" claim-type="Currently amended] The composition of claim 15, further comprising a food in which the t10, c12 octadecadienoic acid is mixed.
    [17" claim-type="Currently amended] The composition of claim 16 wherein the food is for human consumption.
    [18" claim-type="Currently amended] The composition of claim 16, wherein the food is a feed prepared for animal consumption.
    [19" claim-type="Currently amended] Providing an alkali compatible with the seed oil, propylene glycol, and non-aqueous medium containing linoleic acid,
    Blending the seed oil, the propylene glycol, and the alkali compatible with a non-aqueous medium to form a reaction mixture,
    Isomerizing linoleic acid contained in the seed oil by heating to form conjugated linoleic acid, and
    Aqueous phase to release glycerol
    Method for producing a conjugated linoleic acid comprising a.
    [20" claim-type="Currently amended] The method of claim 19, wherein the heating is carried out at 130 to 165 ° C. for about 2 to 6.5 hours.
    [21" claim-type="Currently amended] 20. The method of claim 19, further comprising acidifying to release glycerol, vacuum drying to remove water, and molecular distillation to remove impurities other than conjugated linoleic acid and deodorization.
    [22" claim-type="Currently amended] The method of claim 21, wherein the heating is carried out at 130 to 165 ° C. for about 2 to 6.5 hours.
    [23" claim-type="Currently amended] 20. The method of claim 19, further comprising treating the free fatty acid conjugated linoleic acid with a lipolytic enzyme to form triglycerides.
    [24" claim-type="Currently amended] Providing an alkali compatible with the seed oil, propylene glycol, and non-aqueous medium containing linoleic acid,
    Treating the seed oil containing linoleic acid to form an alkyl ester of linoleic acid,
    Blending the alkylester, the propylene glycol, and the alkali compatible with a non-aqueous medium to form a reaction mixture,
    Isomerizing the alkylester through heating to form conjugated linoleic acid, and
    Aqueous phase to release glycerol
    A method of producing conjugated linoleic acid containing less impurities and biologically active.
    [25" claim-type="Currently amended] The method of claim 24, wherein the heating is carried out at 130 to 165 ° C. for about 2 to 6.5 hours.
    [26" claim-type="Currently amended] Isomerized and blended reaction mixture containing 30 to 60% of the processed seed oil, 10 to 40% of the alkali, and 30 to 60% of the propylene glycol.
    [27" claim-type="Currently amended] Animal feed formulated from biologically active concentrations of conjugated linoleic acid alkylesters with conventional ingredients of typical daily feeds, depending on the species and age of the animal.
    [28" claim-type="Currently amended] The animal feed of claim 27 wherein the concentration of conjugated linoleic acid alkylester in the feed is about 0.05 to 3.5 wt%.
    [29" claim-type="Currently amended] The method of claim 27, wherein the conjugated linoleic acid alkyl ester comprises at least 50% by weight of an octadecanoic acid alkylester isomer selected from the group consisting of c9, t11-octadecanoic acid alkylester and t10, c12-octadecanoic acid alkyl ester An animal feed comprising up to 99% by weight and comprising less than 1% 11,13-octadecanoic acid alkyl ester and trans-trans alkyl ester.
    [30" claim-type="Currently amended] Providing an unpurified linoleic acid alkylester containing phosphatide residues in the range of about 0.1 to about 0.5%,
    Treating with alkali alcoholate at low temperature in the presence of monovalent low molecular weight alcohol to cause at least 50% of the linoleic acid alkyl ester to isomerize to conjugated linoleic acid alkyl ester at low temperature,
    Acidification by addition of aqueous acid, and
    Separating the conjugated linoleic acid alkyl ester from the aqueous acid without distillation
    A method for producing a conjugated linoleic acid alkyl ester for use as a feed for livestock, a food ingredient, or a human dietary supplement.
    类似技术:
    公开号 | 公开日 | 专利标题
    US8524309B2|2013-09-03|Oil or fat composition
    JP4518674B2|2010-08-04|Use of docosapentaenoic acid-containing substances
    US8236854B2|2012-08-07|Lipid-improving agent and composition containing lipid-improving agent
    KR101650584B1|2016-08-23|Polyunsaturated fatty acid-containing solid fat compositions and uses and production thereof
    US9282748B2|2016-03-15|Human breast milk lipid mimetic as a dietary supplement
    CA2418350C|2010-01-19|Oil/fat composition
    AU720158B2|2000-05-25|Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
    JP4761771B2|2011-08-31|Method for producing microbial fats and oils with reduced unsaponifiable matter content and said fats and oils
    AU2003260967B2|2009-12-10|Process for production of transesterified oils/fats or triglycerides
    CA2237883C|2002-02-26|Process for the preparation of materials with a high content of long chain polyunsaturated fatty acids
    JP4391673B2|2009-12-24|Oil composition
    US8685484B2|2014-04-01|Oil compositions of stearidonic acid
    JP4642087B2|2011-03-02|Food compounding agent comprising arachidonic acid-containing edible oil and fat derived from microorganisms, food containing the same, and method for producing arachidonic acid-containing edible oil and fat
    ES2197582T3|2004-01-01|New triglicerido and compositions that contain it.
    ES2201005T3|2004-03-16|Employment of synthetic triglicerids based on conjugated linoleic acid for the obtaining of agents to favor tumors treatment.
    ES2394951T3|2013-02-07|Process for the production of triglycerides
    AU762539B2|2003-06-26|Phytosterol and/or phytostanol derivatives
    US6465666B2|2002-10-15|Isomer enriched CLA compositions
    KR101126305B1|2012-03-19|Process for producing dioleoyl palmitoyl glyceride
    US6479683B1|2002-11-12|Process for conjugating fatty acid esters
    EP1454990B1|2006-02-22|Process for producing unsaturated fatty acid-containing oils
    AU2008237599B2|2015-01-22|Structured lipid compositions and methods of formulation thereof
    CA2293338C|2007-08-28|Isomer enriched conjugated linoleic acid compositions
    US20030175403A1|2003-09-18|Potentiated bioactive additives and method of use
    US8911813B2|2014-12-16|Structured lipid compositions
    同族专利:
    公开号 | 公开日
    WO1999047135A1|1999-09-23|
    NO20004615D0|2000-09-15|
    AU3188699A|1999-10-11|
    EP0950410B1|2007-01-03|
    US20040018225A1|2004-01-29|
    AU764699B2|2003-08-28|
    DE69934627D1|2007-02-15|
    IN2000KO00319A|2005-03-11|
    AT350028T|2007-01-15|
    US6610868B2|2003-08-26|
    CA2289648C|2004-06-01|
    WO1999047135A8|2001-07-05|
    MXPA00009106A|2002-04-01|
    CA2289648A1|1999-09-23|
    DK0950410T3|2007-05-07|
    US7029691B1|2006-04-18|
    US20020169332A1|2002-11-14|
    MX238954B|2006-07-26|
    US6410761B1|2002-06-25|
    ES2279586T3|2007-08-16|
    EP0950410A1|1999-10-20|
    US7514096B2|2009-04-07|
    JP2000516480A|2000-12-12|
    NO331483B1|2012-01-16|
    DE69934627T2|2007-10-25|
    KR100619651B1|2006-09-05|
    NO20004615L|2000-11-07|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    1998-03-17|Priority to US4253898A
    1998-03-17|Priority to US09/042,767
    1998-08-11|Priority to US09/132,593
    1998-09-25|Priority to US09/132,593
    1998-09-25|Priority to US09/042,538
    1998-09-25|Priority to US16041698A
    1998-09-25|Priority to US09/042,767
    1998-09-25|Priority to US09/160,416
    1999-03-17|Application filed by 추후제출, 콘린코 인크.
    1999-03-17|Priority to PCT/US1999/005806
    2001-08-04|Publication of KR20010074447A
    2006-09-05|Application granted
    2006-09-05|Publication of KR100619651B1
    2007-09-27|First worldwide family litigation filed
    优先权:
    申请号 | 申请日 | 专利标题
    US4253898A| true| 1998-03-17|1998-03-17|
    US09/042,767|US6015833A|1998-03-17|1998-03-17|Conjugated linoleic acid compositions|
    US09/132,593|US7078051B1|1998-08-11|1998-08-11|Conjugated linoleic acid alkyl esters in feedstuffs and food|
    US16041698A| true| 1998-09-25|1998-09-25|
    US09/042,767|1998-09-25|
    US09/160,416|1998-09-25|
    US09/132,593|1998-09-25|
    US09/042,538|1998-09-25|
    PCT/US1999/005806|WO1999047135A1|1998-03-17|1999-03-17|Conjugated linoleic acid compositions|
    [返回顶部]